Shots:
- The P-II trial assessed UBT251 (2, 4 & 6 mg, QW, SC) vs PBO & semaglutide (1mg) in 211 Chinese T2D pts, which showed HbA1c reduction of 2.16% vs 1.77% (semaglutide) & 0.66% (PBO) at 24wks. from a baseline of 8.12%
- Trial also showed weight loss of up to 9.8% vs 4.8% (semaglutide) & 1.4% (PBO) from 80.1kg (baseline), plus UBT251 improved waist circumference, BP, & lipids vs PBO. Based on these results, the TUL plans to initiate 2 P-III trials in Chinese T2D pts
- Additionally, Novo initiated a global P-Ib/IIa trial to assess different doses of UBT251 for ~28wks. in ~330 overweight/obese pts, with topline data expected in 2027. Another global P-II trial for T2D is anticipated to begin in H2’26
Ref: Novo Nordisk | Image: The United Laboratories & Novo Nordisk | Press Release
Related News: Novo Nordisk Reports the US FDA Approval of Wegovy HD for Weight Management
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
